After helping lead MYR Pharmaceuticals to a €1.15 billion exit to Gilead Sciences last December, Thomas Christély is ready for his next challenge as the new CEO of MetrioPharm.
ZURICH, Switzerland, Aug. 19, 2021 (GLOBE NEWSWIRE) -- MetrioPharm AG, a pharmaceutical company developing drugs for chronic inflammatory diseases, is expanding its management team. Effective October 1, 2021, Thomas Christély will take on the role as MetrioPharm’s Chief Executive Officer.